Clinical Trial

Phase I Study of HSK41959 in Solid Tumors With MTAP Deletion

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated May 13, 2025 (before its estimated March 26, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a phase I, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK and PD of HSK41959 when given orally in patients with MTAP Deletion locally advanced or metastatic Solid Tumors.
Trial Details
NCT Number NCT06968572
Lead Sponsor Haisco Pharmaceutical Group Co., Ltd.
Conditions Advanced Solid Tumors
Enrollment 245 participants
Start Date 2025-04-11
Primary Completion 2026-03-26 (estimated)
Study Completion 2028-05-08 (estimated)
Updated on ClinicalTrials.gov 2025-05-13